Kellerhals Carrard acted as legal advisor to AdVita

Relief Therapeutics Holding, a biopharmaceutical company whose shares are listed on the SIX Swiss Exchange, and AdVita Lifescience, a Germany-based, privately held pharmaceutical, signed a legally binding term sheet in relation to the acquisition of all shares in AdVita in exchange for EUR 25 million of Relief common shares and, in addition, possible future contingent milestone payments of up to EUR 20 million.

Relief’s lead drug candidate RLF-100TM (Aviptadil) is currently being investigated in two U.S. clinical trials in respiratory deficiency due to Covid-19. AdVita focuses on developing effective products and strategies to improve the treatment and diagnosis of rare lung diseases and has pending intellectual property rights that cover aviptadil inhaled formulation specifications.

The team

Kellerhals Carrard acted as legal advisor to the founders of AdVita in this transaction. The team was led by partner Emanuel Dettwiler (Corporate/M&A – pictured) and comprised senior associate Sophie Holdt (Corporate/M&A). 

Kellerhals Carrard acted as legal advisor to AdVita


Launched in 2020 by LC Publishing Group, it is the first digital portal addressed to the Swiss legal market.
In terms of contents, the website focuses on both law firms and in-house legal departments, covering the latest news and rumors on deals and operations (and the related advisors) as well as on lateral hires, moves and new appointments and providing insights, analytical data and opinions on the professions’ main trends and topics (Ai, innovation, etc.).

For further information, please visit the Group’s website

LC Publishing Group S.p.A. – Via Tolstoi 10 – 20146 Milano – Tel. 0236727659 – C.F./P.IVA 07619210961
REA 1971432 Registro delle Imprese di Milano – Cap. Soc. Euro 50.000,00 i.v.

Copyright 2023 © All rights Reserved. Design by Origami Creative Studio


Share on linkedin
Share on twitter
Share on facebook
Share on whatsapp
Share on email
Share on telegram